Clinical Trial Update: Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 trial update for Combidex USPIO in uterine and cervical neoplasms, completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Neoplasms
• Cervix Neoplasms
• Prostatic Neoplasms
• Uterine Neoplasms

Drugs mentioned

• Combidex USPIO (ferumoxtran-10)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Uterine Neoplasms, Cervix Neoplasms | Phase 1, Phase 2 | Status: COMPLETED